Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 280, Issue 5 49-5, 2001, Pages

  Dendorfer, Andreas ^a   Wolfrum, Sebastian ^a   Wagemann, Marc ^a   Qadri, Fatimunnisa ^a   Dominiak, Peter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Aminopeptidase P; Angiotensin I converting enzyme; Carboxypeptidase N; Kinins; Metabolism

Indexed keywords

AMINOPEPTIDASE P; ARGININE CARBOXYPEPTIDASE; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; KININ; KININASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0035036105     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2001.280.5.h2182     Document Type: Article

References (38)

1. Ahmad S and Ward PE. Depressor action of bradykinin agonists relative to metabolism by angiotensin-converting enzyme, carboxypeptidase N, and aminopeptidase P. Proc Soc Exp Biol Med 200: 115-121, 1992.
2. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H, and Williams RR. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13: 3-8, 1989.
3. Bjornstad-Ostensen A, Holte HR, and Berg T. Amplification of kinin-induced hypotension by nitric oxide synthesis in spontaneously hypertensive rats. Hypertension 29: 53-57, 1997.
4. Bönner G, Preis S, Schunk U, Wagmann M, Chrosch R, and Toussaint C. Effect of bradykinin on arteries and veins in systemic and pulmonary circulation. J Cardiovasc Pharmacol 20: S21-S27, 1992.
5. Casale L, Cardozo C, Kalb T, and Lesser M. Quantitation of endopeptidase 24.11 and endopeptidase 24.15 in human blood leukocytes. Enzyme Protein 48: 143-148, 1994.
6. Dendorfer A, Wolfrum S, and Dominiak P. Pharmacology and cardiovascular implications of the kinin-kallikrein system. Jpn J Pharmacol 79: 403-426, 1999.
7. Dendorfer A, Wolfrum S, Schäfer U, Stewart JM, Inamura N, and Dominiak P. Potentiation of the vascular response to kinins by inhibition of myocardial kininases. Hypertension 35: 32-37, 2000.
8. Dendorfer A, Wolfrum S, Wellhöner P, Korsman K, and Dominiak P. Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. Br J Pharmacol 122: 1179-1187, 1997.
9. Dorer FE, Kahn JR, Lentz KE, Levine M, and Skeggs LT. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ Res 34: 824-827, 1974.
10. Drapeau G, Chow A, and Ward PE. Metabolism of bradykinin analogs by angiotensin I converting enzyme and carboxypeptidase N. Peptides 12: 631-638, 1991.
11. Goetz RM and Holtz J. Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Clin Sci (Colch) 97: 165-174, 1999.
12. Guimaraes JA, Borges DR, Prado ES, and Prado JL. Kininconverting aminopeptidase from human serum. Biochem Pharmacol 22: 3157-3172, 1973.
13. 1H NMR studies. Am J Hematol 25: 183-189, 1987.
14. Ishida H, Scicli AG, and Carretero OA. Contributions of various rat plasma peptidases to kinin hydrolysis. J Pharmacol Exp Ther 251: 817-820, 1989.
15. Izzo JL Jr. Urinary kallikrein levels and hypertension. N Engl J Med 299: 1316-1317, 1978.
16. Jaspard E, Wei L, and Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 268: 9496-9503, 1993.
17. Kitamura S, Carbini LA, Simmons WH, and Scicli AG. Effects of aminopeptidase P inhibition on kinin-mediated vasodepressor responses. Am J Physiol Heart Circ Physiol 276: H1664-H1671, 1999.
18. Kopp UC and Smith LA. Bradykinin and protein kinase C activation fail to stimulate renal sensory neurons in hypertensive rats. Hypertension 27: 607-612, 1996.
19. Kuoppala A, Lindstedt KA, Saarinen J, Kovanen PT, and Kokkonen JO. Inactivation of bradykinin by angiotensin-converting enzyme and by carboxypeptidase N in human plasma. Am J Physiol Heart Circ Physiol 278: H1069-H1074, 2000.
20. Lasch J, Moschner S, Sann H, Zellmer S, and Koelsch R. Aminopeptidase P-a cell-surface antigen of endothelial and lymphoid cells: catalytic and immuno-histotopical evidences, Biol Chem 379: 705-709, 1998.
21. Letarte M, Vera S, Tran R, Addis JB, Onizuka RJ, Quackenbush EJ, Jongeneel CV, and Mclnnes RR. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J Exp Med 168: 1247-1253, 1988.
22. Linz W, Schaper J, Wiemer G, Albus U, and Schölkens BA. Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol 107: 970-975, 1992.
23. Linz W, Wiemer G, Gohlke P, Unger T, and Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25-49, 1995.
24. 2-receptor gene. Circulation 96: 3570-3578, 1997.
25. Maes M, Scharpe S, De M, I, Goossens P, Wauters A, Neels H, Verkerk R, De Meyer F, D'Hondt P, and Peeters D. Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects. Clin Chem 40: 1686-1691, 1994.
26. Majima M, Hayashi I, Inamura N, Fujita T, and Ogino M. A nonpeptide mimic of bradykinin blunts the development of hypertension in young spontaneously hypertensive rats. Hypertension 35: 437-442, 2000.
27. Martins DT, Fior DR, Nakaie CR, and Lindsey CJ. Kinin receptors of the central nervous system of spontaneously hypertensive rats related to the presser response to bradykinin. Br J Pharmacol 103: 1851-1856, 1991.
28. Matsumura T, Kugiyama K, Sugiyama S, Ohgushi M, Amanaka K, Suzuki M, and Yasue H. Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity. J Clin Invest 97: 2192-2203, 1996.
29. O'Sullivan JB and Harrap SB. Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin. Hypertension 25: 162-165, 1995.
30. Orawski AT, Susz JP, and Simmons WH. Metabolism of bradykinin by multiple coexisting membrane-bound peptidases in lung: techniques for investigating the role of each peptidase using specific inhibitors. Adv Exp Med Biol 247B: 355-364, 1989.
31. Plante GE, Bissonnette M, Sirois MG, Regoli D, and Sirois P. Renal permeability alteration precedes hypertension and involves bradykinin in the spontaneously hypertensive rat. J Clin Invest 89: 2030-2032, 1992.
32. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, and Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 86: 1913-1920, 1990.
33. Sheikh IA and Kaplan AP. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem Pharmacol 38: 993-1000, 1989.
34. Skidgel RA, Johnson AR, and Erdös EG. Hydrolysis of opioid hexapeptides by carboxypeptidase N. Presence of carboxypeptidase in cell membranes. Biochem Pharmacol 33: 3471-3478, 1984.
35. Ura N, Shimamoto K, Tanaka S, Nishimiya T, Mita T, Nakagawa M, Maeda T, Yamaguchi Y, and Iimura O. Urinary excretions of kininase I and kininase II activities in essential hypertension. A sensitive and simple method for its kinindestroying capacity. J Clin Hypertens 1: 15-22, 1985.
36. 2 bond of bradykinin by aminopeptidase P. Biochem Pharmacol 44: 479-487, 1992.
37. Ward PE, Chow A, and Drapeau G. Metabolism of bradykinin agonists and antagonists by plasma aminopeptidase P. Biochem Pharmacol 42: 721-727, 1991.
38. Xiong W, Chao J, and Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 25: 715-719, 1995.